margin declined 340bps QoQ due to higher SGA costs. Management maintained that core SGA costs remained lower while the growth in Q2FY20was due to payment on litigation costs. PBT declined by 8% QoQ as trickled down effect of higher SGA costs while PAT decreased by 15% QoQ due to exceptional and extra-ordinary expenditures. Taro guided for exploring opportunities to enhance growth which includes launch more OTC drugs and expand more in other geographies (non-US...